Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Glimepiride 3 mg vs Amaryl® in Healthy Subjects
NCT05468879Phase 1Completed
- Sponsor
- Harsen Laboratories
- Start
- Sep 2020
- Primary completion
- Oct 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glimepiride in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Harsen Laboratories. Primary endpoints: Maximum plasma concentration and Area Under Curve from 0 to 30 hours. Started Sep 2020; status: completed.
02
Drugs
glimepiride
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05468879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468879.